Attendee search 

Leading medical device manufacturer

Macquarie is an Austrian bank company, operating in 31 Markets

TF Capital focuses on investment in the life sciences industry, primarily investing in early stage companies with high potential. Through strategic investments in various key areas and right partnerships, TF Capital hopes to capture opportunities in the rapidly expanding Chinese life sciences market. Our investment team has vast experience and resources in industry to assist our portfolio companies.

CP pharmaceutical group is a leading healthcare player in China. Stock listed in H. K. since 2000.

MNC

A public pharmaceutical company

HitGen is a rapidly growing biotech company with headquarter and main research facility based in Chengdu, China and with a subsidiary in the United States. HitGen has established an industry-leading platform for early-stage drug discovery research centred on the design, synthesis and screening of DNA encoded chemical libraries (DELs).

HitGen’s DELs cover more than 500 billion novel, diverse molecules from different types of chemical libraries, including drug-like/lead-like small molecules, macrocycles, molecules with electrophiles (co-valent binding), protein degraders, molecular fragments, etc,. These compounds are members of DELs synthesized from many hundreds of distinct chemical scaffolds, designed with tractable chemistry, and yielded proven results for the discovery of small molecule leads against precedented and unprecedented classes of biological targets.

In order to support the exploitation of DEL screening output, HitGen has also built structural biology, medicinal chemistry, in vitro and in vivo biology capabilities to support our partner’s drug discovery research projects.

HitGen is collaborating with pharmaceutical, biotech, and chemical companies, foundations and research institutes in North America, Europe, Asia and Africa to discover and develop approaches for novel medicines and other solutions.

HitGen's novel small molecule inhibitor for Class I/IIb HDAC, HG146, is in Phase I clinical trials for Multiple Myeloma. Another new class of second generation TRK/ROS1 inhibitor, HG030, has obtained clinical approval from NMPA. HitGen’s preclinical portfolio includes small molecule IL17A inhibitor and non-nucleoside STING agonist.

http://chinabio-partnering.com/events/CBPF2020/en/home

Listed in China Growth Board, WolwoPharma is the biggest allergen drug manufacturer in China
and the largest allergen preparation supplier in Asia.

Pharmaceutical